Hidradenitis Suppurativa Pipeline Insight
DelveInsight’s, “Hidradenitis Suppurativa - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Hidradenitis Suppurativa Understanding
Hidradenitis Suppurativa: Overview
Hidradenitis suppurativa (HS) is a chronic or relapsing inflammatory skin disease affecting hair follicles in intertriginous areas, including the axillary, inframammary, inguinal, genital, buttocks, and perianal/perineal areas. With a prevalence of 1 to 4 percent, HS is not an uncommon disease. It affects three times as many women as men, and one-third of HS patients report a positive family history. Other predisposing factors include smoking and obesity. The clinical features of HS are recurrent, painful nodules and abscesses, fistulas, sinus tracts (tunnels), and scarring. Patients with HS have significantly impaired quality of life due to both physical and psychological discomfort associated with the disease (e.g., pain, suppuration, social isolation, and work disability). Several conditions, including inflammatory bowel disease, metabolic syndrome, arthritis, and depression, have been reported to co-occur with HS.
"Hidradenitis Suppurativa - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hidradenitis Suppurativa pipeline landscape is provided which includes the disease overview and Hidradenitis Suppurativa treatment guidelines. The assessment part of the report embraces, in depth Hidradenitis Suppurativa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hidradenitis Suppurativa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Hidradenitis Suppurativa R&D. The therapies under development are focused on novel approaches to treat/improve Hidradenitis Suppurativa.
Hidradenitis Suppurativa Emerging Drugs Chapters
This segment of the Hidradenitis Suppurativa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hidradenitis Suppurativa Emerging Drugs
Cosentyx/Secukinumab (Novartis) is an anti-interleukin-17 monoclonal antibody. Hidradenitis suppurativa (HS) is a difficult-to-treat inflammatory skin condition. HS patients have T-helper 17 cell (Th17) axis imbalances that are close to those in psoriasis patients. They have high serum levels of interleukin (IL) 17A proinflammatory cytokine, which contributes to neutrophil recruitment and provides positive feedback to sustain the proinflammatory Th17 cell population. Such imbalances improve with anti-tumor necrosis factor alpha (anti-TNF-alpha) biosimilars. FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis (axSpA) disease spectrum. Currently, the Novartis had completed Phase III stage of drug development for the treatment of Hidradenitis Suppurativa. It has been approved for indications like psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is currently under phase III trial for the treatment of patients affected by HS.
InflaRx's lead drug candidate, IFX-1, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Hidradenitis Suppurativa (HS). The Company requested scientific advice from the European Medicines Agency (EMA) about the European pathway for regulatory approval and received feedback in July 2020. Although the EMA noted certain considerations regarding the Company’s proposal, the EMA acknowledged that HiSCR response does not account for the clinical relevance of a reduction in draining fistulas and the effort to construct a new endpoint that better captures these changes was endorsed in principle. According to the EMA, although HiSCR was used as an endpoint in previous studies, IHS4 could be an appropriate tool to evaluate the efficacy of a novel compound in HS. The Company is working diligently to address the additional feedback received and analyzing the strategy for its Phase III development in HS.
Further product details are provided in the report……..
Hidradenitis Suppurativa: Therapeutic Assessment
This segment of the report provides insights about the different Hidradenitis Suppurativa drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hidradenitis Suppurativa
There are approx. 20+ key companies which are developing the therapies for Hidradenitis Suppurativa. The companies which have their Hidradenitis Suppurativa drug candidates in the most advanced stage, i.e. phase III include, Novartis.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Hidradenitis Suppurativa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hidradenitis Suppurativa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hidradenitis Suppurativa drugs.
Hidradenitis Suppurativa Report Insights
- Hidradenitis Suppurativa Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Hidradenitis Suppurativa Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hidradenitis Suppurativa drugs?
- How many Hidradenitis Suppurativa drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hidradenitis Suppurativa?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hidradenitis Suppurativa therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hidradenitis Suppurativa and their status?
- What are the key designations that have been granted to the emerging drugs?